Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: Target family landscapes

Journal of Medicinal Chemistry

Volumn 45, Issue 12, 2002, Pages 2366-2378

  Naumann, Thorsten ^a   Matter, Hans ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 N (3,3 DIMETHYLALLYL)ADENINE; ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE INHIBITOR; LIGAND; OLOMOUCINE; PROTEIN KINASE; PURINE DERIVATIVE; PURVALANOL A; PURVALANOL B; ROSCOVITINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; LIGAND BINDING; MOLECULAR INTERACTION; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PURINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037030707     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm011002c     Document Type: Article

References (83)

1. The eukaryotic protein kinase super-family: Kinase (catalytic) domain structure and classification
2. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains
3. Eukaryotic protein kinases
4. Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members
5. The structural basis for substrate recognition and control byprotein kinases
6. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity
7. Protein kinase inhibitors
8. Protein kinase inhibitors: The tyrosine-specific protein kinases
9. Inhibitors of serine/threonine kinases
10. Protein kinase inhibitors for the treatment of cancer
11. Recent progress towards the identification of selective inhibitors of serine/threonine kinases
12. Protein kinase superfamily-comparisons of sequence data with three-dimensional structures
13. The structure-based design of ATP site-directed protein kinase inhibitors
14. When fold is not important: A common structural framework for adenine and AMP binding in 12 unrelated protein families
15. The development and therapeutic potential of protein kinase inhibitors
16. Protein kinase inhibitors: Structural determinants for target specificity
17. ATP site-directed competitive and irreversible inhibitors of protein kinases
18. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
19. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure
20. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds
21. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds
22. Principal component analysis
23. Multivariate data analysis and experimental design in biomedical research
24. Multivariate data analysis in chemistry
25. GRID/CPCA: A new computational tool to design selective ligands
26. Analysis of multiblock and hierarchical PCA and PLS models
27. A search for specificity in DNA-drug interactions
28. A novel strategy for improving ligand selectivity in receptor-based drug design
29. Affinity and selectivity of metrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins
30. A view on affinity and selectivity of nonpeptidic matrix metalloproteinase inhibitors from the perspective of ligands and target
31. Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: Toward more specific ligands
32. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors
33. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors
34. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
35. Comparative Molecular Field Analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins
36. Comparative Molecular Field Analysis (CoMFA). 2. Towards its use with 3D-structural databases
37. Comparative molecular similarity indeces in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity
38. Molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries
39. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa
40. Comparative molecular similarity indices analysis. CoMSIA
41. Multivariate structure - Activity relationship between data from a battery of biological tests and an ensemble of structure descriptors: The PLS methodol
42. Notes on the history and nature of partial least squares (PLS) modelling
43. Cross-validatory estimation of the number of component in factor and principal component models
44. Computer-intensive methods for statistics
45. Crossvalidation, bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies
46. Maximally diagonal force constants in dependent angle-bending coordinates. II. Implications for the design of empirical force fields
47. MMFF VI. MMFF94s option for energy minimization studies
48. The protein data bank
49. Knowledge-based protein modeling and design
50. Knowledge-based modeling of homologous proteins. Part I: Three-dimensional frameworks derived from the simultaneous superposition of multiple structures
51. Knowledge based modeling of homologous proteins. Part II: Rules for the conformations of substituted side chains
52. 2.2 Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with manganese ATP and a peptide inhibitor
53. Crystal structures of the catalytic subunit of cAMP-dependent protein kinase reveal general features of the protein kinase family
54. Generating Optimal Linear PLS Estimations (GOLPE): An advanced chemometric tool for handling 3DQSAR problems
55. Hierarchical multiblock PLS and PC models for easier model interpretation and as an alternative to variable selection
56. An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap
57. Recommendations for CoMFA studies and 3D QSAR publications
58. CoMFA: Scope and limitations
59. The developing practice of comparative molecular field analysis
60. Extending the trend vector: The trend matrix and sample-based partial least squares
61. The probability of chance correlation using partial least squares (PLS)
62. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics
63. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
64. Inhibition of cyclin-dependent kinases by purine analogues
65. Biochemical and cellular effects ofroscovitine, a potent and selective inhibitor of cyclin-dependent kinases cdc2, cdk2 and cdk5
66. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation
67. Synthesis and activity of 2,6,9-trisubstituted purines
68. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases
69. 2,6,9-Trisubstituted purines: Optimization toward highly potent and selective CDK1 inhibitors
70. Multiple modes of ligand recognition: Crystal structure of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine
71. Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine